Vienna-based molecular biology institute excelling in chromosome organization, cryo-EM structural biology, and regeneration research through ERC-funded programs.
The IMP (Research Institute of Molecular Pathology) is a premier basic research institute in Vienna focused on understanding fundamental molecular mechanisms in biology — how genes are regulated, how chromosomes are organized, how cells develop and regenerate. Their work spans chromosome biology (particularly cohesin-mediated genome architecture), structural biology using cryo-electron microscopy, RNA processing, cancer biology, and tissue regeneration in model organisms like axolotl and zebrafish. As a privately structured research institute (Boehringer Ingelheim-funded), they operate with the agility of a company but the mission of an academic lab, attracting top postdoctoral fellows through competitive programs like VIP-2.
Five dedicated projects (CohesinMolMech, Cohesin loading, LoopMechRegFun, mcMINFLUX, Enhancer ID) spanning 2015-2026 trace a continuous line from cohesion mechanisms to loop extrusion and genome architecture.
RNApaxport, StructuRNP, TREXSpliceosome, and NANO4LIFE all rely on cryo-EM or advanced imaging for structural determination of molecular complexes.
RNApaxport, StructuRNP, and TREXSpliceosome focus on mRNA packaging, snRNP biogenesis, and TREX-mediated export respectively.
RegGeneMems, REANIMA, Imagine, TRANSPOLOTL, and AxoMatrx study regenerative mechanisms across axolotl limb, cardiac tissue, and neural circuits.
CombaTCancer, Evomet, and AML-SynergyX address therapy resistance in metastatic cancer, metastasis evolution, and targeted therapies in leukemia.
NANO4LIFE (super-resolution, single molecule tracking), mcMINFLUX (MINFLUX nanoscopy), and WideBrainImaging demonstrate expanding imaging technology development.
In 2015-2018, IMP's H2020 portfolio centered on chromosome biology — cohesin, sister chromatid cohesion, chromatin structure — alongside fluorescence microscopy development and transcriptional regulation. From 2019 onward, a clear shift emerged toward structural biology powered by cryo-EM, RNA biology (mRNA export, snRNP biogenesis), and regeneration biology in axolotl and zebrafish models. The institute also broadened into translational areas: cardiac regeneration (REANIMA), cancer combination therapies (AML-SynergyX), and proteomics infrastructure (EPIC-XS), suggesting a move from purely mechanistic questions toward applications informed by their basic science strengths.
IMP is investing heavily in cryo-EM and MINFLUX nanoscopy as enabling platforms, positioning itself to offer structural insights into RNA processing and genome organization complexes — expect future projects combining these imaging capabilities with their biological expertise.
IMP overwhelmingly leads its own projects: 23 of 30 grants are as coordinator, reflecting a PI-driven culture built around ERC and MSCA individual fellowships rather than large collaborative consortia. Most projects are single-PI grants with no or few partners, which means they operate independently and attract talent rather than building large networks. When they do join consortia (EPIC-XS, REANIMA, NeuroMag), they contribute specialized expertise — this is an institute you approach for deep scientific capability, not for project management or consortium coordination.
With 46 unique partners across 17 countries, IMP has a broad but relatively thin European network — a consequence of their PI-grant-heavy portfolio where most projects have few partners. Their collaborations span Western and Central Europe with no strong geographic clustering.
IMP stands out as one of Europe's most successful institutes at securing competitive individual excellence grants (ERC + MSCA), with a 77% coordination rate that reflects genuine scientific leadership rather than administrative convenience. Their combination of deep chromosome biology expertise with rapidly growing cryo-EM structural capabilities creates a rare profile: they can study a molecular machine both functionally and structurally in-house. For potential partners, IMP offers access to world-class principal investigators and postdoctoral talent in a compact, well-funded private research environment — ideal for projects needing fundamental mechanistic insights rather than applied development.
